
0:00
8:38
Let us know your thoughts. We would love to hear from you.
Dr. Nero speaks with Dr. Greg Katz of NYU about the neutral topline results of the Lp(a) HORIZON trial and their implications for patient care. Beyond the trial readout, they explore how these findings reshape expectations that lowering Lp(a) will improve cardiovascular outcomes—and how to counsel and treat patients amid this uncertainty. They discuss current strategies, potential alternatives, and emerging therapies that may provide new answers. Although the results raise more questions than they resolve, the conversation remains centered on what matters most: patients.
Altri episodi di "Patient Pulse"



Non perdere nemmeno un episodio di “Patient Pulse”. Iscriviti all'app gratuita GetPodcast.








